Assessing the Uptake of the Lung Cancer Core Outcome Set: A Cross-Sectional Analysis
Introduction: A core outcome set (COS) helps standardize outcome measurements across clinical trials. Although lung cancer is the leading cause of cancer-related deaths, research exploring COS implementation across lung cancer trials remains limited. We aim to analyze the uptake of the lung cancer C...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | JTO Clinical and Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666364324000833 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846136504984797184 |
|---|---|
| author | Andrew V. Tran, BS Brody Dennis, BS Matthew Rashid, BS Kyle Fitzgerald, BS Garrett Jones, BS Kimberly Magana, MEd Jay Modi, BS Trevor Magee, BS Shaelyn Ward, BS Griffin Hughes, BA, BS Alicia Ito Ford, PhD Matt Vassar, PhD |
| author_facet | Andrew V. Tran, BS Brody Dennis, BS Matthew Rashid, BS Kyle Fitzgerald, BS Garrett Jones, BS Kimberly Magana, MEd Jay Modi, BS Trevor Magee, BS Shaelyn Ward, BS Griffin Hughes, BA, BS Alicia Ito Ford, PhD Matt Vassar, PhD |
| author_sort | Andrew V. Tran, BS |
| collection | DOAJ |
| description | Introduction: A core outcome set (COS) helps standardize outcome measurements across clinical trials. Although lung cancer is the leading cause of cancer-related deaths, research exploring COS implementation across lung cancer trials remains limited. We aim to analyze the uptake of the lung cancer COS and identify potential gaps in COS adherence. Methods: On June 26, 2023, we conducted a cross-sectional analysis of clinical trials that evaluated lung cancer interventions. Our sample consisted of studies registered on ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform between September 2011 and June 2023. In a masked and duplicate fashion, investigators extracted data regarding trial characteristics and COS adoption. An interrupted time series analysis was conducted to evaluate the adherence of lung cancer COS before and after its publication. Results: Of the 626 observed trials, we found no overall significant difference in lung cancer COS uptake pre- and post-publication (0.01%, 95% confidence interval: −0.16% to 0.19%, p=0.85). The most frequently measured outcomes were “overall survival” (91.69%%) and “treatment-related mortalities” (54.69%). Health-related quality of life questionnaires were typically used to evaluate outcomes in the “Degree of health” domain (49.20%). Outcomes related to “time from diagnosis to treatment” (0%), “place of death” (0.16%), and “duration of time spent in the hospital at the end of life” (1.60%) were rarely measured. Conclusions: Despite the advantages of COS implementation, adherence across lung cancer clinical trials remains alarmingly low—which could compromise data reliability and patient care. Our findings showcase these inconsistencies and emphasize the need for proactive approaches to improve uptake. |
| format | Article |
| id | doaj-art-eb8bab44aa404ffb8ae10ad3c0ebb41c |
| institution | Kabale University |
| issn | 2666-3643 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JTO Clinical and Research Reports |
| spelling | doaj-art-eb8bab44aa404ffb8ae10ad3c0ebb41c2024-12-09T04:28:05ZengElsevierJTO Clinical and Research Reports2666-36432024-12-01512100713Assessing the Uptake of the Lung Cancer Core Outcome Set: A Cross-Sectional AnalysisAndrew V. Tran, BS0Brody Dennis, BS1Matthew Rashid, BS2Kyle Fitzgerald, BS3Garrett Jones, BS4Kimberly Magana, MEd5Jay Modi, BS6Trevor Magee, BS7Shaelyn Ward, BS8Griffin Hughes, BA, BS9Alicia Ito Ford, PhD10Matt Vassar, PhD11Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma; Corresponding author. Address for correspondence: Andrew V. Tran, BS, Oklahoma State University Center for Health Sciences, 1111 W 17th Street, Tulsa, OK 74107.Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, OklahomaOffice of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, OklahomaOffice of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, OklahomaOffice of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, OklahomaOffice of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, OklahomaOffice of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, OklahomaOffice of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, OklahomaOffice of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, OklahomaOffice of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, OklahomaOffice of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma; Department of Psychiatry and Behavioral Sciences, Oklahoma State University Center for Health Sciences, Tulsa, OklahomaOffice of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma; Department of Psychiatry and Behavioral Sciences, Oklahoma State University Center for Health Sciences, Tulsa, OklahomaIntroduction: A core outcome set (COS) helps standardize outcome measurements across clinical trials. Although lung cancer is the leading cause of cancer-related deaths, research exploring COS implementation across lung cancer trials remains limited. We aim to analyze the uptake of the lung cancer COS and identify potential gaps in COS adherence. Methods: On June 26, 2023, we conducted a cross-sectional analysis of clinical trials that evaluated lung cancer interventions. Our sample consisted of studies registered on ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform between September 2011 and June 2023. In a masked and duplicate fashion, investigators extracted data regarding trial characteristics and COS adoption. An interrupted time series analysis was conducted to evaluate the adherence of lung cancer COS before and after its publication. Results: Of the 626 observed trials, we found no overall significant difference in lung cancer COS uptake pre- and post-publication (0.01%, 95% confidence interval: −0.16% to 0.19%, p=0.85). The most frequently measured outcomes were “overall survival” (91.69%%) and “treatment-related mortalities” (54.69%). Health-related quality of life questionnaires were typically used to evaluate outcomes in the “Degree of health” domain (49.20%). Outcomes related to “time from diagnosis to treatment” (0%), “place of death” (0.16%), and “duration of time spent in the hospital at the end of life” (1.60%) were rarely measured. Conclusions: Despite the advantages of COS implementation, adherence across lung cancer clinical trials remains alarmingly low—which could compromise data reliability and patient care. Our findings showcase these inconsistencies and emphasize the need for proactive approaches to improve uptake.http://www.sciencedirect.com/science/article/pii/S2666364324000833Lung cancerCore outcome setsClinical trialsAdherenceUptake |
| spellingShingle | Andrew V. Tran, BS Brody Dennis, BS Matthew Rashid, BS Kyle Fitzgerald, BS Garrett Jones, BS Kimberly Magana, MEd Jay Modi, BS Trevor Magee, BS Shaelyn Ward, BS Griffin Hughes, BA, BS Alicia Ito Ford, PhD Matt Vassar, PhD Assessing the Uptake of the Lung Cancer Core Outcome Set: A Cross-Sectional Analysis JTO Clinical and Research Reports Lung cancer Core outcome sets Clinical trials Adherence Uptake |
| title | Assessing the Uptake of the Lung Cancer Core Outcome Set: A Cross-Sectional Analysis |
| title_full | Assessing the Uptake of the Lung Cancer Core Outcome Set: A Cross-Sectional Analysis |
| title_fullStr | Assessing the Uptake of the Lung Cancer Core Outcome Set: A Cross-Sectional Analysis |
| title_full_unstemmed | Assessing the Uptake of the Lung Cancer Core Outcome Set: A Cross-Sectional Analysis |
| title_short | Assessing the Uptake of the Lung Cancer Core Outcome Set: A Cross-Sectional Analysis |
| title_sort | assessing the uptake of the lung cancer core outcome set a cross sectional analysis |
| topic | Lung cancer Core outcome sets Clinical trials Adherence Uptake |
| url | http://www.sciencedirect.com/science/article/pii/S2666364324000833 |
| work_keys_str_mv | AT andrewvtranbs assessingtheuptakeofthelungcancercoreoutcomesetacrosssectionalanalysis AT brodydennisbs assessingtheuptakeofthelungcancercoreoutcomesetacrosssectionalanalysis AT matthewrashidbs assessingtheuptakeofthelungcancercoreoutcomesetacrosssectionalanalysis AT kylefitzgeraldbs assessingtheuptakeofthelungcancercoreoutcomesetacrosssectionalanalysis AT garrettjonesbs assessingtheuptakeofthelungcancercoreoutcomesetacrosssectionalanalysis AT kimberlymaganamed assessingtheuptakeofthelungcancercoreoutcomesetacrosssectionalanalysis AT jaymodibs assessingtheuptakeofthelungcancercoreoutcomesetacrosssectionalanalysis AT trevormageebs assessingtheuptakeofthelungcancercoreoutcomesetacrosssectionalanalysis AT shaelynwardbs assessingtheuptakeofthelungcancercoreoutcomesetacrosssectionalanalysis AT griffinhughesbabs assessingtheuptakeofthelungcancercoreoutcomesetacrosssectionalanalysis AT aliciaitofordphd assessingtheuptakeofthelungcancercoreoutcomesetacrosssectionalanalysis AT mattvassarphd assessingtheuptakeofthelungcancercoreoutcomesetacrosssectionalanalysis |